Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Edwards Lifesciences Corp., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Net income (loss) 335,300 340,100 489,500 338,200 309,500 325,200 (121,900) 310,600 280,200 274,700 242,300 249,700 7,000 225,900 282,700 206,600 (2,800) 170,100 186,100 230,200
Depreciation and amortization 33,000 33,600 35,800 32,400 32,600 25,600 24,500 24,500 23,900 23,100 21,700 20,600 19,900 19,200 19,200 19,100 21,200 20,700 18,900 21,100
Non-cash operating lease cost 7,100 7,100 7,000 7,300 7,500 7,400 6,600 6,700 6,600 6,900 6,100 5,700
Stock-based compensation 24,200 26,600 30,300 28,200 20,900 23,000 24,800 23,900 18,400 19,800 22,300 20,800 16,000 17,400 19,200 18,400 15,300 15,800 15,300 15,200
Inventory write off 26,900 46,200
Impairment charges 40,600 118,800 31,000
Change in fair value of contingent consideration liabilities (18,100) 1,100 (102,600) (4,500) 5,200 (9,000) 19,600 (2,200) (18,500) (2,300) 8,000 6,700 (14,000) (6,400) 10,900 3,800 2,600 (16,700) 3,100 1,100
Deferred income taxes (61,500) 3,900 5,400 10,800 (11,600) 1,400 (42,800) 3,600 2,600 (3,400) 7,100 5,800 (57,100) 10,900 (12,200) 31,100 (26,300) 400 7,100 36,600
Purchase of intellectual property 24,000 1,000 100 5,600
Other (7,100) (3,100) (10,500) (2,700) (4,100) (4,200) (9,900) 14,700 2,000 2,900 (700) (7,000) 10,000 1,000 1,000 1,000 (4,000) (1,200) (400) (600)
Accounts and other receivables, net 6,800 38,000 (46,400) (89,500) 51,100 (30,700) 25,700 (4,200) (17,700) 18,900 (43,400) (45,800) (28,400) (2,900) (27,300) 29,900 10,500 56,100 11,000 (81,500)
Inventories (6,600) 8,100 15,000 2,500 (2,400) (19,000) (64,000) (35,200) (21,500) (22,000) (32,500) (29,400) (22,200) (23,000) (17,200) (3,300) (14,200) (37,600) (47,900) (24,300)
Accounts payable and accrued liabilities 31,100 79,300 94,100 (9,300) (30,600) 81,400 9,100 (144,400) 45,700 81,400 231,600 (242,200) 188,500 93,200 28,800 (118,000) 36,600 112,400 30,400 (94,200)
Income taxes 33,000 5,800 9,100 14,100 12,700 (74,700) (23,100) 32,200 26,200 20,500 12,800 (16,300) 50,800 (19,700) (182,200) (6,700) 333,400 (9,000) (65,000) 19,000
Prepaid expenses and other current assets 6,400 1,100 5,800 (5,400) (6,400) (21,800) 5,400 (5,700) (4,300) (6,400) 1,100 2,800 4,800 22,400 14,900 (26,400) (10,000) (1,200) 4,900 (3,600)
Litigation settlement accrual (10,100) (22,800) 2,100 1,600 1,300 (98,700) 367,900 (180,000)
Other 100 13,100 (8,500) (23,200) 14,300 10,200 9,300 (17,500) 15,200 (3,700) (1,400) 6,100 (1,100) 4,300 2,400 (4,200) 1,600 3,100 3,700
Changes in operating assets and liabilities 60,700 122,600 71,200 (109,200) 40,000 (153,300) 330,300 (174,800) 43,600 88,700 (11,800) (324,800) 192,400 74,300 (180,600) (128,700) 357,900 120,700 (63,500) (180,900)
Adjustments to reconcile net income (loss) to net cash provided by operating activities 38,300 191,800 36,600 (37,700) 90,500 (109,100) 353,100 (103,600) 119,200 162,600 98,900 (248,200) 286,000 116,400 (142,500) (55,300) 366,700 140,700 11,600 (101,900)
Net cash provided by operating activities 373,600 531,900 526,100 300,500 400,000 216,100 231,200 207,000 399,400 437,300 341,200 1,500 293,000 342,300 140,200 151,300 363,900 310,800 197,700 128,300
Capital expenditures (89,800) (60,700) (69,300) (106,000) (113,200) (103,300) (108,300) (82,200) (71,500) (76,100) (64,600) (42,200) (57,600) (85,100) (52,800) (43,200) (51,900) (42,300) (58,000) (15,900)
Deposit of cash in escrow (25,000)
Purchases of held-to-maturity investments (147,000) (68,000) (35,000) (50,000) (112,000) (100,200) (30,000) (20,000) (190,000) (88,000) (211,300) (505,600)
Proceeds from held-to-maturity investments 68,000 20,000 50,000 112,000 100,200 30,000 20,000 190,000 48,600 101,000 238,500 321,700 101,000 2,500 229,500
Purchases of available-for-sale investments (907,300) (345,500) (299,100) (77,400) (295,400) (118,600) (124,800) (150,900) (342,900) (19,600) (75,400) (134,000) (115,300) (52,000) (145,500) (164,900) (167,400)
Proceeds from available-for-sale investments 129,100 93,600 81,700 86,800 206,500 103,300 127,200 127,800 81,600 87,500 134,700 56,100 30,100 92,000 58,800 42,300 67,700 91,600 96,100 193,300
Investments in intangible assets (4,000) (300) (7,200) (16,800) (3,000) (1,000) (3,700) (2,700)
Acquisitions (100,200) (108,000) (100) (2,800) (82,000)
Payment for acquisition option (7,400) (5,700) (10,000) (35,000)
Issuances of notes receivable (1,500) (3,600) (500) (4,600) (5,300) (16,600) (4,500) (3,000) (4,700) (700)
Collections of notes receivable 10,000 10,000
Other (16,000) (16,800) (12,100) 500 (7,000) (3,100) (1,000) (1,000) (7,800) (1,500) (900) (900) (2,800) (4,400) (2,100) (14,300) (15,200) (1,900) (1,800) (3,600)
Net cash (used in) provided by investing activities (965,900) (377,400) (329,500) (49,700) (259,900) (126,300) (10,200) (134,700) (445,300) (12,700) (88,300) (49,500) 5,700 (254,200) 104,900 220,300 49,300 (209,500) (638,200) 151,200
Proceeds from issuance of debt (8,800) 9,500 4,500 3,900 1,700 2,700 7,900 6,900 2,300 6,000 3,700 1,600 600 680,700 5,100 5,400 3,900 608,000 377,400
Payments on debt and finance lease obligations (100) 8,700 (10,700) (4,900) (3,000) (2,200) (3,600) (8,200) (5,200) (3,500) (16,200) (4,000) (601,200) (1,900) (517,100) (5,100) (5,600) (4,600) (454,800) (353,400)
Purchases of treasury stock (96,500) (1,800) (111,900) (302,600) (200) (1,400) (9,000) (614,800) (1,300) (256,300) (5,700) (272,000) (173,100) (348,200) (2,200) (251,300) (800) (73,800) (437,400)
Equity forward contract related to accelerated share repurchase agreement 80,000 (80,000)
Proceeds from stock plans 33,900 38,900 54,200 31,600 37,000 36,100 38,300 29,100 35,000 39,000 41,500 45,000 27,700 35,000 39,600 44,700 22,500 22,600 45,600 23,100
Payment of contingent consideration (15,100)
Other 700 2,000 (100) (2,900) 3,700 (200) (4,300) (400) 300 (2,100) (6,400) 5,400 (800) 2,700 (600) (1,600) (800) 1,800 (1,000)
Net cash provided by (used in) financing activities (62,000) 39,000 (59,000) (274,300) 41,400 34,000 24,100 (586,400) 37,000 34,400 (231,400) 44,400 (844,700) (56,700) (240,700) 40,900 (229,000) 20,300 126,800 (391,300)
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash 1,800 500 (2,600) 14,200 (10,600) (3,300) (4,500) (2,100) 1,400 800 (3,900) (1,300) (1,200) 3,500 (5,000) (3,800) 3,800 500 2,600 1,000
Net increase (decrease) in cash, cash equivalents, and restricted cash (652,500) 194,000 135,000 (9,300) 170,900 120,500 240,600 (516,200) (7,500) 459,800 17,600 (4,900) (547,200) 34,900 (600) 408,700 188,000 122,100 (311,100) (110,800)

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Edwards Lifesciences Corp. net cash provided by operating activities increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Edwards Lifesciences Corp. net cash (used in) provided by investing activities decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Edwards Lifesciences Corp. net cash provided by (used in) financing activities increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.